ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
September 30, 2020

Total Share Capital Notification Admission to trading on Euronext Growth Brussels of newly issued ordinary shares

Read More
September 30, 2020

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2020

Read More
September 29, 2020

Share Subscription into Incanthera plc (“Incanthera”)

Read More
September 22, 2020

Repayment of Convertible Security – Lind Global Macro Fund, LP

Read More
September 11, 2020

Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

Read More
September 10, 2020

Conversion of Convertible Security – Lind Global Macro Fund, LP

Read More
September 09, 2020

Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund

Read More
September 08, 2020

TR1 – Notification of major interest in shares by Lanstead Capital

Read More
September 08, 2020

Director/PDMR Shareholding/TR-1

Read More
September 07, 2020

Placing to raise £6.5 million – update; related party transaction

Read More
September 03, 2020

Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund

Read More
September 02, 2020

Placing to raise £6.5 million

Read More
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 24
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved